STINGing Antitumor Immunity into Action.

  • Published 2018 in Cancer discovery


Efforts to stimulate STING signaling, thereby turning immunologically "cold" tumors "hot" and receptive to immunotherapy, are gaining ground in the industry. To date, directly targeting the STING receptor with synthetic ligands is the main approach to have entered clinical trials, but indirect small-molecule modulators of the pathway are also being pursued.


0 Figures and Tables

    Download Full PDF Version (Non-Commercial Use)